Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

PDE Inhibitors for the Treatment of Schizophrenia.

Snyder GL, Vanover KE.

Adv Neurobiol. 2017;17:385-409. doi: 10.1007/978-3-319-58811-7_14. Review.

PMID:
28956340
2.

Preclinical profile of ITI-214, an inhibitor of phosphodiesterase 1, for enhancement of memory performance in rats.

Snyder GL, Prickaerts J, Wadenberg ML, Zhang L, Zheng H, Yao W, Akkerman S, Zhu H, Hendrick JP, Vanover KE, Davis R, Li P, Mates S, Wennogle LP.

Psychopharmacology (Berl). 2016 Sep;233(17):3113-24. doi: 10.1007/s00213-016-4346-2. Epub 2016 Jun 24.

3.

Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and Future.

Li P, Snyder GL, Vanover KE.

Curr Top Med Chem. 2016;16(29):3385-3403. Review.

4.

Discovery of Potent and Selective Inhibitors of Phosphodiesterase 1 for the Treatment of Cognitive Impairment Associated with Neurodegenerative and Neuropsychiatric Diseases.

Li P, Zheng H, Zhao J, Zhang L, Yao W, Zhu H, Beard JD, Ida K, Lane W, Snell G, Sogabe S, Heyser CJ, Snyder GL, Hendrick JP, Vanover KE, Davis RE, Wennogle LP.

J Med Chem. 2016 Feb 11;59(3):1149-64. doi: 10.1021/acs.jmedchem.5b01751. Epub 2016 Feb 2.

PMID:
26789933
5.

ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial.

Lieberman JA, Davis RE, Correll CU, Goff DC, Kane JM, Tamminga CA, Mates S, Vanover KE.

Biol Psychiatry. 2016 Jun 15;79(12):952-61. doi: 10.1016/j.biopsych.2015.08.026. Epub 2015 Aug 31.

6.

ITI-007 demonstrates brain occupancy at serotonin 5-HT₂A and dopamine D₂ receptors and serotonin transporters using positron emission tomography in healthy volunteers.

Davis RE, Vanover KE, Zhou Y, Brašić JR, Guevara M, Bisuna B, Ye W, Raymont V, Willis W, Kumar A, Gapasin L, Goldwater DR, Mates S, Wong DF.

Psychopharmacology (Berl). 2015 Aug;232(15):2863-72. doi: 10.1007/s00213-015-3922-1. Epub 2015 Apr 7.

7.

Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission.

Snyder GL, Vanover KE, Zhu H, Miller DB, O'Callaghan JP, Tomesch J, Li P, Zhang Q, Krishnan V, Hendrick JP, Nestler EJ, Davis RE, Wennogle LP, Mates S.

Psychopharmacology (Berl). 2015 Feb;232(3):605-21. doi: 10.1007/s00213-014-3704-1. Epub 2014 Aug 15.

8.

Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders.

Li P, Zhang Q, Robichaud AJ, Lee T, Tomesch J, Yao W, Beard JD, Snyder GL, Zhu H, Peng Y, Hendrick JP, Vanover KE, Davis RE, Mates S, Wennogle LP.

J Med Chem. 2014 Mar 27;57(6):2670-82. doi: 10.1021/jm401958n. Epub 2014 Mar 5.

PMID:
24559051
9.
10.

Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans.

Warner-Schmidt JL, Vanover KE, Chen EY, Marshall JJ, Greengard P.

Proc Natl Acad Sci U S A. 2011 May 31;108(22):9262-7. doi: 10.1073/pnas.1104836108. Epub 2011 Apr 25. Erratum in: Proc Natl Acad Sci U S A. 2011 Jul 5;108(27):11297.

11.

Pimavanserin tartrate, a 5-HT(2A) receptor inverse agonist, increases slow wave sleep as measured by polysomnography in healthy adult volunteers.

Ancoli-Israel S, Vanover KE, Weiner DM, Davis RE, van Kammen DP.

Sleep Med. 2011 Feb;12(2):134-41. doi: 10.1016/j.sleep.2010.10.004. Epub 2011 Jan 21.

12.

Role of 5-HT2A receptor antagonists in the treatment of insomnia.

Vanover KE, Davis RE.

Nat Sci Sleep. 2010 Jul 28;2:139-50. Print 2010.

13.

Identification of novel selective V2 receptor non-peptide agonists.

Del Tredici AL, Vanover KE, Knapp AE, Bertozzi SM, Nash NR, Burstein ES, Lameh J, Currier EA, Davis RE, Brann MR, Mohell N, Olsson R, Piu F.

Biochem Pharmacol. 2008 Oct 30;76(9):1134-41. doi: 10.1016/j.bcp.2008.08.004. Epub 2008 Aug 12.

PMID:
18761325
14.

A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model.

Vanover KE, Betz AJ, Weber SM, Bibbiani F, Kielaite A, Weiner DM, Davis RE, Chase TN, Salamone JD.

Pharmacol Biochem Behav. 2008 Oct;90(4):540-4. doi: 10.1016/j.pbb.2008.04.010.

15.

Antipsychotic-like behavioral effects and cognitive enhancement by a potent and selective muscarinic M-sub-1 receptor agonist, AC-260584.

Vanover KE, Veinbergs I, Davis RE.

Behav Neurosci. 2008 Jun;122(3):570-5. doi: 10.1037/0735-7044.122.3.570.

PMID:
18513127
16.

Assessment of learning and memory using the autoshaping of operant responding in mice.

Barrett JE, Vanover KE.

Curr Protoc Neurosci. 2004 Feb;Chapter 8:Unit 8.5F. doi: 10.1002/0471142301.ns0805fs25.

PMID:
18428609
17.

Pharmacological characterization of AC-262536, a novel selective androgen receptor modulator.

Piu F, Gardell LR, Son T, Schlienger N, Lund BW, Schiffer HH, Vanover KE, Davis RE, Olsson R, Bradley SR.

J Steroid Biochem Mol Biol. 2008 Mar;109(1-2):129-37. doi: 10.1016/j.jsbmb.2007.11.001. Epub 2007 Nov 22.

PMID:
18164613
18.

PET analysis of the 5-HT2A receptor inverse agonist ACP-103 in human brain.

Nordstrom AL, Mansson M, Jovanovic H, Karlsson P, Halldin C, Farde L, Vanover KE, Hacksell U, Brann MR, Davis RE, Weiner DM.

Int J Neuropsychopharmacol. 2008 Mar;11(2):163-71. Epub 2007 Aug 21.

PMID:
17708779
19.

Pharmacology of N-desmethylclozapine.

Lameh J, Burstein ES, Taylor E, Weiner DM, Vanover KE, Bonhaus DW.

Pharmacol Ther. 2007 Aug;115(2):223-31. Epub 2007 May 21. Review.

PMID:
17583355
20.

ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models.

Gardell LR, Vanover KE, Pounds L, Johnson RW, Barido R, Anderson GT, Veinbergs I, Dyssegaard A, Brunmark P, Tabatabaei A, Davis RE, Brann MR, Hacksell U, Bonhaus DW.

J Pharmacol Exp Ther. 2007 Aug;322(2):862-70. Epub 2007 May 22.

21.

The effects of food on the pharmacokinetics of a formulated ACP-103 tablet in healthy volunteers.

Vanover KE, Robbins-Weilert D, Wilbraham DG, Mant TG, van Kammen DP, Davis RE, Weiner DM.

J Clin Pharmacol. 2007 Jul;47(7):915-9. Epub 2007 May 10. No abstract available.

PMID:
17495279
22.

Pharmacokinetics, tolerability, and safety of ACP-103 following single or multiple oral dose administration in healthy volunteers.

Vanover KE, Robbins-Weilert D, Wilbraham DG, Mant TG, van Kammen DP, Davis RE, Weiner DM.

J Clin Pharmacol. 2007 Jun;47(6):704-14. Epub 2007 May 1.

PMID:
17473118
23.

Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist.

Vanover KE, Weiner DM, Makhay M, Veinbergs I, Gardell LR, Lameh J, Del Tredici AL, Piu F, Schiffer HH, Ott TR, Burstein ES, Uldam AK, Thygesen MB, Schlienger N, Andersson CM, Son TY, Harvey SC, Powell SB, Geyer MA, Tolf BR, Brann MR, Davis RE.

J Pharmacol Exp Ther. 2006 May;317(2):910-8. Epub 2006 Feb 9.

24.

The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine.

Weiner DM, Meltzer HY, Veinbergs I, Donohue EM, Spalding TA, Smith TT, Mohell N, Harvey SC, Lameh J, Nash N, Vanover KE, Olsson R, Jayathilake K, Lee M, Levey AI, Hacksell U, Burstein ES, Davis RE, Brann MR.

Psychopharmacology (Berl). 2004 Dec;177(1-2):207-16. Epub 2004 Jul 16.

PMID:
15258717
25.

Pharmacological characterization of AC-90179 [2-(4-methoxyphenyl)-N-(4-methyl-benzyl)-N-(1-methyl-piperidin-4-yl)-acetamide hydrochloride]: a selective serotonin 2A receptor inverse agonist.

Vanover KE, Harvey SC, Son T, Bradley SR, Kold H, Makhay M, Veinbergs I, Spalding TA, Weiner DM, Andersson CM, Tolf BR, Brann MR, Hacksell U, Davis RE.

J Pharmacol Exp Ther. 2004 Sep;310(3):943-51. Epub 2004 Apr 21.

26.

Psychosis of Parkinson's disease: serotonin 2A receptor inverse agonists as potential therapeutics.

Weiner DM, Vanover KE, Brann MR, Meltzer HY, Davis RE.

Curr Opin Investig Drugs. 2003 Jul;4(7):815-9. Review.

PMID:
14619402
27.

Psychiatric Drug Discovery & Development--SRI Conference. 23-24 June 2003, Princeton, NJ, USA.

Vanover KE.

IDrugs. 2003 Aug;6(8):739-42. No abstract available.

PMID:
12971389
28.

5-hydroxytryptamine2A receptor inverse agonists as antipsychotics.

Weiner DM, Burstein ES, Nash N, Croston GE, Currier EA, Vanover KE, Harvey SC, Donohue E, Hansen HC, Andersson CM, Spalding TA, Gibson DF, Krebs-Thomson K, Powell SB, Geyer MA, Hacksell U, Brann MR.

J Pharmacol Exp Ther. 2001 Oct;299(1):268-76.

29.
30.
31.
32.

Neuroactive steroids attenuate cocaine-induced sucrose intake in rats, but not cocaine-induced hyperactivity in mice.

Vanover KE, Suruki M, Huber M, Wilent WB, Carter RB.

Psychopharmacology (Berl). 2000 Apr;149(3):269-76.

PMID:
10823408
33.

Response-rate suppression in operant paradigm as predictor of soporific potency in rats and identification of three novel sedative-hypnotic neuroactive steroids.

Vanover KE, Edgar DM, Seidel WF, Hogenkamp DJ, Fick DB, Lan NC, Gee KW, Carter RB.

J Pharmacol Exp Ther. 1999 Dec;291(3):1317-23.

34.

Pharmacological evaluation of a modified conflict procedure: punished drinking in non-water-deprived rats.

Vanover KE, Robledo S, Huber M, Carter RB.

Psychopharmacology (Berl). 1999 Aug;145(3):333-41.

PMID:
10494583
35.

Interaction of ethanol with excitatory amino acid receptor antagonists in mice.

Vanover KE.

Eur J Pharmacol. 1999 Mar 5;368(2-3):137-42.

PMID:
10193649
36.

Positive allosteric modulators of the GABA(A) receptor: differential interaction of benzodiazepines and neuroactive steroids with ethanol.

Vanover KE, Suruki M, Robledo S, Huber M, Wieland S, Lan NC, Gee KW, Wood PL, Carter RB.

Psychopharmacology (Berl). 1999 Jan;141(1):77-82.

PMID:
9952068
37.
38.

Synthesis of 7,8-(methylenedioxy)-1-phenyl-3,5-dihydro-4H-2, 3-benzodiazepin-4-ones as novel and potent noncompetitive AMPA receptor antagonists.

Wang Y, Konkoy CS, Ilyin VI, Vanover KE, Carter RB, Weber E, Keana JF, Woodward RM, Cai SX.

J Med Chem. 1998 Jul 2;41(14):2621-5.

PMID:
9651166
39.

Effects of AMPA receptor antagonists on dopamine-mediated behaviors in mice.

Vanover KE.

Psychopharmacology (Berl). 1998 Mar;136(2):123-31.

PMID:
9551768
40.
41.

Discriminative stimulus effects of the endogenous neuroactive steroid pregnanolone.

Vanover KE.

Eur J Pharmacol. 1997 May 30;327(2-3):97-101.

PMID:
9200546
42.

Behavioral effects of the dopamine autoreceptor agonist PD 128483 alone and in combination with cocaine.

Vanover KE, Woolverton WL.

J Pharmacol Exp Ther. 1994 Sep;270(3):1049-56.

PMID:
7932152
43.

Evaluation of the discriminative stimulus effects of the novel sedative-hypnotic CL 284,846.

Vanover KE, Barrett JE.

Psychopharmacology (Berl). 1994 Jul;115(3):289-96.

PMID:
7871067
44.

Effects of cholecystokinin antagonists on the discriminative stimulus effects of cocaine in rats and monkeys.

Massey BW, Vanover KE, Woolverton WL.

Drug Alcohol Depend. 1994 Jan;34(2):105-11.

PMID:
8026297
45.

Evaluation of the reinforcing and discriminative stimulus effects of cocaine in combination with (+)-AJ76 or clozapine.

Vanover KE, Piercey MF, Woolverton WL.

J Pharmacol Exp Ther. 1993 Aug;266(2):780-9.

PMID:
8355207
46.

5-HT receptors as targets for the development of novel anxiolytic drugs: models, mechanisms and future directions.

Barrett JE, Vanover KE.

Psychopharmacology (Berl). 1993;112(1):1-12. Review.

PMID:
7870996
47.

Reinforcing effect of the D1 dopamine agonist SKF 81297 in rhesus monkeys.

Weed MR, Vanover KE, Woolverton WL.

Psychopharmacology (Berl). 1993;113(1):51-2.

PMID:
7862828
48.

Evaluation of the discriminative stimulus and reinforcing effects of sertraline in rhesus monkeys.

Vanover KE, Nader MA, Woolverton WL.

Pharmacol Biochem Behav. 1992 Apr;41(4):789-93.

PMID:
1594647
49.
50.

Self-administration of the isomers of pentobarbital and secobarbital by rhesus monkeys.

Vanover KE, Wenger GR, Woolverton WL.

Pharmacol Biochem Behav. 1989 Nov;34(3):669-71.

PMID:
2623024

Supplemental Content

Loading ...
Support Center